4D Molecular Therapeutics, Inc. (FDMT) vs MiMedx Group, Inc. (MDXG)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and MiMedx Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.83HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
MDXG
MiMedx Group, Inc.
$4.60HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — FDMT vs MDXG
growth of $100 · dividends reinvested · last 6yFDMT -68.1% (-17.3%/yr)MDXG -22.5% (-4.2%/yr)MDXG compounded faster over this window
FDMT MDXG
FDMT vs MDXG: by the numbers
- •FDMT is the larger company ($671M vs $670M market cap).
- •MDXG is profitable (1.76% net margin) while FDMT runs a net loss (-194.74%).
- •FDMT grew revenue faster over the past five years (31.93% vs 6.36% CAGR).
Metrics side by side
Valuation
| Metric | FDMT | MDXG |
|---|---|---|
| P/E ratio | N/A | 114.88 |
| P/S ratio | 7.29 | 1.89 |
| P/B ratio | 1.65 | 3.10 |
| EV / EBITDA | N/A | 26.24 |
| FCF yield | N/A | 6.06% |
Profitability
| Metric | FDMT | MDXG |
|---|---|---|
| Gross margin | 91.05% | 78.85% |
| Operating margin | -187.24% | 15.26% |
| Net margin | -194.74% | 1.76% |
| ROE | -43.95% | 2.89% |
| ROIC | -44.30% | 1.97% |
Growth (annualized)
| Metric | FDMT | MDXG |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | 6.36% |
| Total return CAGR (5Y) | -13.08% | -4.94% |
Frequently asked
- Which has grown faster, FDMT or MDXG?
- Over the past five years, FDMT grew revenue faster — FDMT at a 31.93% CAGR versus MDXG at 6.36%.
- Is FDMT or MDXG more profitable?
- MDXG runs the higher net margin — FDMT at -194.74% versus MDXG at 1.76%.
- How have FDMT and MDXG total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and MDXG delivered -4.94% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
MiMedx P/E ratio4D Molecular Therapeutics ROEMiMedx ROE4D Molecular Therapeutics operating marginMiMedx operating margin4D Molecular Therapeutics revenue growthMiMedx revenue growth4D Molecular Therapeutics free cash flowMiMedx free cash flow
4D Molecular Therapeutics & MiMedx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.